Panbela Therapeutics (OTCMKTS:PBLA – Get Free Report) is expected to announce its resultson Thursday, May 14th. Analysts expect the company to announce earnings of ($2,640.00) per share for the quarter.
Panbela Therapeutics Stock Performance
OTCMKTS:PBLA opened at $0.00 on Tuesday. The company has a fifty day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01. Panbela Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.31.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc (NASDAQ: PBLA) is a clinical‐stage biotechnology company focused on developing first‐in‐class therapies that modulate polyamine metabolism to treat aggressive cancers. The company’s lead investigational compound, SBP-101, is a proprietary stabilized spermine analogue designed to induce tumor cell apoptosis by dysregulating polyamine levels. Panbela has centered its pipeline largely on SBP-101 in combination with standard‐of‐care regimens for high‐mortality indications such as metastatic pancreatic adenocarcinoma and high‐risk myelodysplastic syndromes (HR-MDS).
In its pancreatic cancer program, Panbela is evaluating SBP-101 alongside gemcitabine and nab-paclitaxel in a Phase 1b/2 study, with interim data having been presented at major oncology conferences.
Further Reading
- Five stocks we like better than Panbela Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
